Correspondence 0001193125-24-152304 from Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc.
Date: June 3, 2024 · CIK: 0002012593 · Accession: 0001193125-24-152304
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279486
Letter
VIA EDGAR AND FEDERAL EXPRESS Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do Re: Rapport Therapeutics, Inc. Registration Statement on Form S-1 Filed May 17, 2024 File No. 333-279486
Dear Ladies and Gentlemen:
This letter is submitted on behalf of Rapport Therapeutics, Inc. (the “Company”), in response to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 filed on May 17, 2024 (the “Registration Statement”), as set forth in the Staff’s letter, dated May 24, 2024, addressed to Troy Ignelzi (the “Comment Letter”). The Company is concurrently publicly filing the Amendment No. 1 to the Registration Statement on Form S-1 (the “Amendment No. 1”).
For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Unless otherwise indicated, page references in the descriptions of the Staff’s comments refer to the Registration Statement, and page references in the responses refer to the Amendment No. 1. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Amendment No. 1.
Risks Associated With Our Business, page 7
1. We note your revised disclosure at the bottom of page 29 in response to prior comment 1. Please add a new Summary risk factor bullet point that highlights this specific risk.
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
June 3, 2024
Page
RESPONSE: The Company acknowledges the Staff’s comment and has revised its disclosure on page 7 of Amendment No. 1 in response to the Staff’s comment.
[Signature Page Follows]
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
June 3, 2024
Page
If you should have any questions concerning the enclosed matters, please contact the undersigned at (617) 570-1222.
Sincerely,
/s/ Kingsley L. Taft
Show Raw Text
CORRESP 1 filename1.htm CORRESP Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 June 3, 2024 VIA EDGAR AND FEDERAL EXPRESS Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do Re: Rapport Therapeutics, Inc. Registration Statement on Form S-1 Filed May 17, 2024 File No. 333-279486 Dear Ladies and Gentlemen: This letter is submitted on behalf of Rapport Therapeutics, Inc. (the “Company”), in response to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 filed on May 17, 2024 (the “Registration Statement”), as set forth in the Staff’s letter, dated May 24, 2024, addressed to Troy Ignelzi (the “Comment Letter”). The Company is concurrently publicly filing the Amendment No. 1 to the Registration Statement on Form S-1 (the “Amendment No. 1”). For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Unless otherwise indicated, page references in the descriptions of the Staff’s comments refer to the Registration Statement, and page references in the responses refer to the Amendment No. 1. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Amendment No. 1. Risks Associated With Our Business, page 7 1. We note your revised disclosure at the bottom of page 29 in response to prior comment 1. Please add a new Summary risk factor bullet point that highlights this specific risk. Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission June 3, 2024 Page 2 RESPONSE: The Company acknowledges the Staff’s comment and has revised its disclosure on page 7 of Amendment No. 1 in response to the Staff’s comment. [Signature Page Follows] Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission June 3, 2024 Page 3 If you should have any questions concerning the enclosed matters, please contact the undersigned at (617) 570-1222. Sincerely, /s/ Kingsley L. Taft Kingsley L. Taft, Esq. cc: Abraham N. Ceesay, Rapport Therapeutics, Inc. Troy Ignelzi, Rapport Therapeutics, Inc. Stephanie A. Richards, Goodwin Procter LLP Justin S. Platt, Goodwin Procter LLP Richard Segal, Cooley LLP Divakar Gupta, Cooley LLP Darah Protas, Cooley LLP